Biorestorative Therapies, INC 10-Q quarterly reports

BioRestorative Therapies, Inc. reported a narrowed net loss for Q1 2026, improved working capital, and a strengthened cash position, though it faces Nasdaq minimum bid price non-compliance.

BioRestorative Therapies, Inc. reported a significant increase in net loss and cash burn for Q3 and the nine months ended September 30, 2025, raising substantial doubt about its ability to continue as a going concern.

BioRestorative Therapies, Inc. reported increased revenue driven by new product sales but continued significant net losses and a going concern warning, alongside identified material weaknesses in internal controls.

BioRestorative Therapies' Q1 2025 results reveal a widened net loss due to increased research and development expenses, despite a slight decrease in revenue.

BioRestorative Therapies reported its third quarter 2024 results, showing increased revenue and providing updates on its financial position and clinical programs.

BioRestorative Therapies reports a net loss of $6.3 million for the first half of 2024, but also highlights $7.5 million in net proceeds from a warrant exercise program.

BioRestorative Therapies reported a net loss of $2.2 million for the first quarter of 2024, a significant decrease compared to a $7.2 million loss in the same period last year.